The bill aims to assess emerging treatments for treatment-resistant post-traumatic stress disorder (PTSD) in military and civilian first responder personnel, acknowledging existing therapies' limitations. It references a clinical trial evaluating psilocybin for PTSD and urges the Department of Defense to analyze the trial's data and its potential impact on force health and suicide prevention. The bill focuses on safety, dosing, regulatory considerations, continuity of care, and resource needs for potential expanded research or pilot activities, with collaboration from various government agencies. A report must be submitted within 180 days to congressional defense committees. The bill emphasizes the importance of evaluating emerging clinical research for service members and veterans with treatment-resistant PTSD.